These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23921801)

  • 1. [New drugs in oncology: benefits, risks and challenges].
    Cella D; Vervölgyi V; Wörmann B
    Onkologie; 2013; 36 Suppl 5():12-9. PubMed ID: 23921801
    [No Abstract]   [Full Text] [Related]  

  • 2. [Targeted therapy: old and new possibilities].
    Hochhaus A; Lüftner D; Mackensen A
    Onkologie; 2013; 36 Suppl 5():2-11. PubMed ID: 23921800
    [No Abstract]   [Full Text] [Related]  

  • 3. [Adequate supportive treatment in therapeutic use of "biologicals" for GI tumours in oncosurgery--what does the surgeon need to know?].
    Kettner E; Hütten H; Ricke J; Meyer F
    Zentralbl Chir; 2013 Apr; 138(2):204-9. PubMed ID: 23564552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modern anti-cancer therapy: current state and future developments].
    Bokemeyer C; Hiddemann W
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2067. PubMed ID: 25268204
    [No Abstract]   [Full Text] [Related]  

  • 5. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
    Jensen LH; Jakobsen A
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin care for cancer patients.
    Lacouture ME
    Clin Adv Hematol Oncol; 2012 Nov; 10(11):748-50. PubMed ID: 23271263
    [No Abstract]   [Full Text] [Related]  

  • 7. Is tumor response important for renal carcinoma?
    Inman BA; George DJ
    Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical studies in oncology--a challenge for clinical and academic pathology].
    Röcken C
    Dtsch Med Wochenschr; 2013 May; 138(20):1073-6. PubMed ID: 23670265
    [No Abstract]   [Full Text] [Related]  

  • 9. Side effects of targeted therapies. Introduction.
    Eaby-Sandy B
    Semin Oncol Nurs; 2014 Aug; 30(3):137-8. PubMed ID: 25085024
    [No Abstract]   [Full Text] [Related]  

  • 10. New antineoplastic therapies and inherent risks: monoclonal antibodies, biologic response modifiers and interleukin-2.
    Dillman JB
    J Intraven Nurs; 1989; 12(2):103-13. PubMed ID: 2475596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are predictions of cancer response to targeted drugs, based on effects in unrelated tissues, the 'Black Swan' events?
    Kurbel B; Golem AZ; Kurbel S
    Future Oncol; 2015; 11(16):2307-14. PubMed ID: 26260809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Are targeted therapies better tolerated?].
    Stiefelhagen P
    MMW Fortschr Med; 2015 Apr; 157(7):23-4. PubMed ID: 26012443
    [No Abstract]   [Full Text] [Related]  

  • 13. Biologic agents in the treatment of colorectal cancer: the last decade; the lost decade?
    Venook AP; Saltz LB
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714476
    [No Abstract]   [Full Text] [Related]  

  • 14. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.
    Neal JW; Sledge GW
    Nat Rev Clin Oncol; 2014 Nov; 11(11):627-8. PubMed ID: 25286974
    [No Abstract]   [Full Text] [Related]  

  • 16. [Current aspects and medication therapy strategies for out-patient uro-oncological therapy].
    Rinnab L; Küfer R
    Urologe A; 2009 Nov; 48(11):1261-2. PubMed ID: 19844671
    [No Abstract]   [Full Text] [Related]  

  • 17. Pediatric Development of Molecularly Targeted Oncology Drugs.
    Patel SK; Leong R; Zhao H; Barone A; Casey D; Liu Q; Burckart GJ; Reaman G
    Clin Pharmacol Ther; 2018 Aug; 104(2):384-389. PubMed ID: 29226303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.
    Borovicka JH; Calahan C; Gandhi M; Abraham TS; Kwasny MJ; Haley AC; West DP; Lacouture ME
    Arch Dermatol; 2011 Dec; 147(12):1403-9. PubMed ID: 22184762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical guidance on the perioperative use of targeted agents in solid tumor oncology.
    Mellor JD; Cassumbhoy M; Jefford M
    Asia Pac J Clin Oncol; 2011 Jun; 7(2):106-13. PubMed ID: 21585689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loading doses for costly cancer biologicals: sound pharmacology or unnecessary extravagance?
    Epstein RJ; Cheung BM
    Eur J Cancer; 2008 Jul; 44(11):1488-92. PubMed ID: 18194858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.